Incyte

positive negative up down good bad mixed
Biotech

Incyte posts phase 3 skin condition wins but details disappoint

With the response rate down on phase 2, the results drew unfavorable comparisons to rival data and triggered a 15% drop in the biotech’s share price.
Nick Paul Taylor Mar 17, 2025 8:12am
Gems gemstones diamonds precious treasure

Incyte pens $885M AI pact to use Genesis' GEMS to develop drugs

Feb 20, 2025 8:00am
Deal terminate tear up end deal scrap

Incyte exits cancer pact, leaving Agenus weighing its options

Feb 11, 2025 7:55am
Golfer devastated after just barely missing a putt

Incyte scraps cancer-related anemia program after ph. 1/2 fail

Dec 13, 2024 2:30pm
pause hold stop delay

Incyte's $750M buyout rocked by pause on key trial, asset cull

Nov 19, 2024 4:12am
pipeline pipes RD research

Incyte drops two PD-L1 drugs as part of 2nd pipeline clear-out

Jul 30, 2024 8:14am